Lehrstuhl für Geburtshilfe und Frauenheilkunde

Does Anti-Müllerian hormone vary during a menstrual cycle? A systematic review and meta-analysis (2022) Khodavirdilou R, Pournaghi M, Rastgar Rezaei Y, Hajizadeh K, Khodavirdilou L, Javid F, Hamdi K, et al. Journal article, Review article Sex-specific association between prenatal androgenization (second-to-fourth digit length ratio) and frontal brain volumes in adolescents (2022) Lenz B, Gerhardt S, Boroumand-Jazi R, Eichler A, Buchholz VN, Fasching P, Kornhuber J, et al. Journal article Orofacial clefts lead to increased pro-inflammatory cytokine levels on neonatal oral mucosa (2022) Seidel CL, Percivalle E, Tschaftari M, Weider M, Strobel K, Willershausen I, Unertl C, et al. Journal article Machine Learning-based Detection of In-Utero Fetal Presentation from Non-Invasive Fetal ECG (2022) Jäger K, Nissen M, Richer R, Rahm S, Titzmann A, Fasching P, Eskofier B, Leutheuser H Conference contribution, Conference Contribution Matching adjusted indirect comparison of PFS & OS comparing ribociclib plus letrozole vs palbociclib plus letrozole as first-line treatment of HR+/HER2-ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2 (2022) Jhaveri K, O'Shaughnessy J, Fasching P, Cardoso F, Tolaney S, Hamilton E, Sharma VK, et al. Conference contribution Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT) (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC) (2022) Loibl S, Reinisch M, Denkert C, Schneeweiss A, Seiler S, Fasching P, Hanusch C, et al. Conference contribution Expression of disialoganglioside GD2 in breast cancer subtypes (2022) Gaß P, Kailayangiri S, Hübner H, Rübner M, Hartmann A, Häberle L, Völkl S, et al. Conference contribution Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522 (2022) Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur H, Kuemmel S, Bergh J, et al. Conference contribution Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response (2022) Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, Furlanetto J, et al. Journal article